An update on bicalutamide in the treatment of prostate cancer

Bibliography

• SCHELLHAMMER P: Bicalutamide (Casodex'). Exp. Opin. Invest. Drugs (1996) 5:1707–1722.
   Google Scholar
• WINGO PA, LANDIS S, RIES LAG: An adjustment to the 1997 estimate for new prostate cancer cases. CA. Cancer J. Clin. (1997) 47:239–242.
   PubMed Web of Science ®Google Scholar
• LANDIS SH, MURRAY T, BOLDEN S, WINGO PA: Cancer statistics, 1998. CA. Cancer J. Clin. (1998) 48:6–29.
   PubMed Web of Science ®Google Scholar
• TYRRELL CJ: Adjuvant and neoadjuvant hormonal therapy for prostate cancer. Eur. Urol. (1999) In prepara-tion.
   Google Scholar
• ••A comprehensive review of neoadjuvant and adjuvanttherapy.
   Google Scholar
• FURR BJ, TUCKER H: The preclinical development of bicalutamide: pharmacodynamics and mechanism of action. Urology (1996) 47 (Suppl. 1 a):13–25.
   Google Scholar
• COCKSHOTT ID, SOTANIEMI EA, COOPER KJ, JONES DC: The pharmacokinetics of Casodex enantiomers in subjects with impaired liver function. Br. J. Clin. Pharmacol. (1993) 36:339–343.
   PubMed Web of Science ®Google Scholar
• COCKSHOTT ID, COOPER KJ, SWEETMORE DS et al.: The pharmacokinetics of Casodex in prostate cancer patients after single and during multiple dosing. Eur. Urol. (1990) 18\(Suppl. 3):10–17.
   Google Scholar
• BLACKLEDGE G, KOLVENBAG G, NASH A: Bicalutamide: a new antiandrogen for use in combination with castration for patients with advanced prostate cancer. Anti-Cancer Drugs (1996) 7:27–34.
   PubMed Web of Science ®Google Scholar
• BLACKLEDGE GRP: High-dose bicalutamide monotherapy for the treatment of prostate cancer. Urology (1996) 47 (Suppl. 1 a):44–47.
   Google Scholar
• KOLVENBAG GJCM, BLACKLEDGE GRP, GOTTING-SMITH K: Bicalutamide (Casodex) in the treatment of prostate cancer: history of clinical development. Prostate (1998) 34:61–72.
   PubMed Web of Science ®Google Scholar
• BLACKLEDGE GRP: Clinical progress with a new antian-drogen, Casodex (bicalutamide). Eur. Urol. (1996) 2:96–104.
   Google Scholar
• TYRRELL CJ: Casodex: a pure non-steroidal anti-androgen used as monotherapy in advanced prostate cancer. Prostate (1992) 4\(Suppl. 4):97–104.
   Google Scholar
• LUNGLMAYR G: Efficacy and tolerability of Casodex patients with advanced prostate cancer. Anti-Cancer Drugs (1995) 6:508–513.
   PubMed Web of Science ®Google Scholar
• SOLOWAY MS, SCHELLHAMMER PF, SMITH JA et al.: Bicalutamide in the treatment of advanced prostate carcinoma: a Phase II non-comparative multicenter trial evaluating safety, efficacy and long-term endocrine effects of monotherapy. j Um]. (1995) 154:2110–2114.
   Web of Science ®Google Scholar
• KUCUK 0, BLUMENSTEIN B, MOINPOUR C et al.: Phase IItrial of Casodex in advanced prostate cancer (CaP) patients who failed conventional hormonal manipula-tion: a SouthWest Oncology Group (SWOG) study (SWOG 9235). Proceedings of ASCO (1996) 15:245. Abstract 618.
   Google Scholar
• BUBLEY GJ, BALK SP: Treatment of androgen independent prostate cancer. The Oncologist (1996) 1:30–35.
   PubMedGoogle Scholar
• LIEBERTZ G, KELLY WK, THEODOULOU M et al.: High-dose Casodex® for prostate cancer (PC) declines in patients (pts) with flutamide withdrawal responses. Proc. Am. Soc. Clin. Oncol. (1995) 232: Abstract 603.
   Google Scholar
• BALES GT, CHODAK GW: A controlled trial of bicaluta-mide versus castration in patients with advanced prostate cancer. Urology (1996) 47\(Suppl. 1438–43.
   Google Scholar
• SCHELLHAMMER P, SHARIFI R, BLOCK N et al.: Acontrolled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone releasing hormone analogue therapy, in patients with advanced prostate cancer. Urology (1995) 45:745–752.
   PubMed Web of Science ®Google Scholar
• SCHELLHAMMER P, SHARIFI R, BLOCK N et al.: Maximalandrogen blockade for patients with metastatic prostate cancer: outcome of a controlled trial of bicalu-tamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy. Urology (1996) 47 (Suppl. 1A):54–60.
   Google Scholar
• SCHELLHAMMER PF, SHARIFI R, BLOCK NL et al.: Acontrolled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone releasing hormone analogue therapy, in patients with advanced prostate cancer: analysis of time to progression. Cancer (1996) 78:2164–2169.
   PubMed Web of Science ®Google Scholar
• SCHELLHAMMER PF, SHARIFI R, BLOCK NL et al: Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized multicenter trial. Urology (1997) 50:330–336.
   PubMed Web of Science ®Google Scholar
• ••A head-to-head comparison of the efficacy and tolerabilityof two anti-androgens in CAB.
   Google Scholar
• SCHELLHAMMER P, VENNER P, HAAS G et al.: Prostate-specific antigen decreases after withdrawal of antian-drogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J. Urol. (1997) 157:1731–1735.
   PubMed Web of Science ®Google Scholar
• FURR BJA: Relative potencies of flutamide and`Casodex'. Endocr. Relat. Cancer (1997) 4:197–202.
   Web of Science ®Google Scholar
• KOLVENBAG GJCM, FURR BJA, BLACKLEDGE GRP: Receptor affinity and potency of non-steroidal antian-drogens: translation of preclinical findings into clinical activity. Prost. Canc. Prost. Dis. (1998) 1:307–314.
   PubMed Web of Science ®Google Scholar
• SIMARD J, SINGH SM, LABRIE F: Comparison of in vitro effects of pure antiandrogens OH-flutamide, Casodex, and nilutamide on androgen sensitive parameters. Urology (1997) 49:580–589.
   PubMed Web of Science ®Google Scholar
• LUO S, MARTEL C, CHEN C et al.: Daily dosing with flutamide or Casodex exerts maximal antiandrogenic activity. Urology (1997) 50:913–919.
   PubMed Web of Science ®Google Scholar
• BROULIK PD, STARKA L: Effect of antiandrogens Casodex and epitestosterone on bone composition in mice. Bone (1997) 20:473–475.
   PubMed Web of Science ®Google Scholar
• McKILLOP D, BUTTERS CJ, HILL SJ, SIMONS PJ, EDWARDSTL, DOUGHTY SE: Enzyme-inducing effects of bicaluta-mide in mouse, rat and dog. Xenobiotica (1998) 28:465–478.
   PubMed Web of Science ®Google Scholar
• KAISARY A, KLARSKOV P, McKILLOP D: Absence of hepatic enzyme induction in prostate cancer patients receiving `Casodex' (bicalutamide). Anti-Cancer Drugs (1996) 7:54–59.
   PubMed Web of Science ®Google Scholar
• VELDSCHOLTE J, RIS-STALPERS C, KUIPER GG et al.: Amutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem. Biophys. Res. Commun. (1990) 173:534–540.
   PubMed Web of Science ®Google Scholar
• KEMPPAINEN JA, WILSON EM: Agonist and antagonistactivities of hydroxyflutamide and Casodex relate to androgen receptor stabilization. Urology (1996) 48:157–163.
   PubMed Web of Science ®Google Scholar
• FENTON MA, SHUSTER TD, FERTIG AM et al.: Functionalcharacterization of mutant androgen receptors from androgen-independent prostate cancer. Clin. Cancer Res. (1997) 3:1383–1388.
   PubMed Web of Science ®Google Scholar
• TSUKAMOTO S, AKASA H, ONOZAWA M, SHIRAI T, IDEYAMA T: A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer (1998) 82:531–537.
   PubMed Web of Science ®Google Scholar
• HENDRY DS, KIRK D, WHELDON T, LEAKE RE: The effects of combining the antiandrogen bicalutamide with hyperthermia and radiation on prostate cell lines in vitro. Br. J. Urol. (1998) 81 (Suppl. 4):29. Abstract 89.
   Google Scholar
• COCKSHOTT ID, OLIVER SD, YOUNG JJ, COOPER KJ, JONES DC: The effect of food on the pharmacokinetics of the bicalutamide ('Casodex') enantiomers. Biopharm. Drug Dispos. (1997) 18:499–507.
   PubMed Web of Science ®Google Scholar
• FOSSA SD, AASS N, OPJORDSMOEN S: Assessment of quality of life in patients with prostate cancer. Semin. Oncol. (1994) 21:657–661.
   PubMed Web of Science ®Google Scholar
• IVERSEN P, TYRRELL CJ, KAISARY AV et al: Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicentre randomized trials at a median follow-up of 4 years. Urology (1998) 51:389–396.
   PubMed Web of Science ®Google Scholar
• ••A large randomised trial of anti-androgen monotherapycompared with castration.
   Google Scholar
• TYRRELL CJ, KAISARY AV, IVERSEN P etal.: A randomised of `Casodex' (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur. Urol. (1998) 33:447–456.
   Google Scholar
• ••A mature analysis of anti-androgen monotherapy comparedwith castration.
   Google Scholar
• KAISARY AV, IVERSEN P, TYRRELL CJ et al.: Exploratory post-hoc survival evaluation in M1 prostate cancer patients treated with bicalutamide (Casodex). Ann. Oncol. (1998) 9\(Suppl. 4):57. Abstract 2730.
   Google Scholar
• FABOZZI SJ, KOLM P, SCHELLHAMMER PF: PSA response to secondary androgen deprivation following failed treatment of metastatic prostate cancer with the antiandrogen Casodex. Urol. Oncol (1995) 1:64–66.
   PubMedGoogle Scholar
• SCHER HI, LIEBERTZ C, KELLY WK et al.: Bicalutamide for advanced prostate cancer: the natural versus treated history of disease. J. Clin. Oncol (1997) 15:2928–2938.
   PubMed Web of Science ®Google Scholar
• •A study which looks at the influence of disease stage and prior therapy on response to treatment.
   Google Scholar
• FOURCADE RO, CHATELAIN C, POTERRE M: An open multicentre randomised study to compare the effect and safety of Casodex (bicalutamide) 150 mg monotherapy with castration plus nilutamide in metastatic prostate cancer. Eur. Urol. (1998) 33 (Suppl. 1):88. Abstract 349.
   Google Scholar
• FOURCADE RO, CHATELAIN C, HAGUENAUER D: Can combined androgen blockade treatment of metastatic prostate cancer be challenged by monotherapy using bicalutamide 150 mg? Gynecol. Endocrin. (1999) 13 (Suppl. 0:47. Abstract 94.
   Google Scholar
• DITONNO P, BATTAGLIA M, SELVAGGI FP et al.: Bicaluta-mide (B) monotherapy versus flutamide (F) plus goserelin in prostate cancer (Ca) patients (Pts). Preliminary results of an Italian Prostate Cancer Group (PONCAP) study. J. Urol. (1998) 159:130. Abstract 490.
   Google Scholar
• FERRARIS V, DELLI PONTI U, BARICHELLO M etal: Bicalu-tamide (B) monotherapy versus flutamide (F) plus goserelin (G) in prostate cancer (Ca) patients (Pts). Preliminary results of an Italian Prostate Cancer Group (PONCAP) study. Eur. Urol. (1998) 33\(Suppl. 1):88. Abstract 350.
   Google Scholar
• RUBAGOTTI, BOCCARDO F, CANOBBIO L et al.: Evalua-tion of quality of life (QL) of prostate cancer patients (Pts) during up front therapy with either Casodex© monotherapy or goserelin plus flutamide (GF). Proc. Am. Soc. Clin. Oncol (1998) 17:341. Abstract 1315.
   Google Scholar
• SAROSDY MF, SCHELLHAMMER PF, SHARIFI R et al.: of goserelin and leuprolide in combined androgen blockade therapy. Urology (1998) 52:82–88.
   PubMed Web of Science ®Google Scholar
• ••An analysis of the effect of components of CAB on efficacyand tolerability of treatment.
   Google Scholar
• JOYCE R, FENTON MA, RODE P et al: High dose bicaluta- for androgen independent prostate cancer: effect of prior hormonal therapy. J. Urol. (1998) 159:149–153.
   PubMed Web of Science ®Google Scholar
• •A paper exploring the treatment of androgen independent disease.
   Google Scholar
• CHATELAIN C, FOURCADE RO, DELCHAMBRE J: Bicaluta-mide (Casodex®) versus combined androgen blockade: open French multicentre trial in patients with metastatic prostate cancer. Br. J. Urol. (1997) 80\(Suppl. 2):283. Abstract 1111.
   Google Scholar
• HART W, STRICKER BH: Flutamide and hepatitis. Ann. Intern. Med. (1989) 110:943–944.
   PubMed Web of Science ®Google Scholar
• PESCATORE P, HAMMEL P, DURAND F et al.: Hepatic fulminante mortelle imputable au nilutamide (Anandron) [Fatal fulminant hepatitis induced by (Anandron)]. Gastroenterol. Clin. Biol. (1993) 17:499–501.
   PubMedGoogle Scholar
• WYSOWSKI DK, FOURCROY JL: Flutamide hepatotox-icity. j Urol. (1996) 155:209–212.
   PubMedGoogle Scholar
• DAWSON LA, CHOW E, MORTON G: Fulminant hepatic failure associated with bicalutamide. Urology (1997) 49:283–284.
   PubMed Web of Science ®Google Scholar
• CHODAK GW: Bicalutamide-associated fulminant hepatic failure. Urology (1997) 50:1027.
   PubMed Web of Science ®Google Scholar
• SCHELLHAMMER PF: Fulminant hepatic failure associ-ated with bicalutamide. Urology (1997) 50:827 (Letter).
   Google Scholar
• CHATELAIN C, ROUSSEAU V, COSAERT J: French multicenter trial comparing Casodex (ICI 176,334) monotherapy with castration plus nilutamide in metastatic prostate cancer: a preliminary report. Eur. Urol. (1994) 26\(Suppl. 0:10–14.
   Google Scholar
• PFITZENMEYER P, FOUCHER P, PIARD F et al.: Niluta-mide pneumonitis: a report on eight patients. Thorax (1992) 47:622–627.
   PubMed Web of Science ®Google Scholar
• SEIGNEUR J, TRECHOT PF, HUBERT J, LAMY P: Pulmonary complications of hormone treatment in prostate carcinoma. Chest (1988) 93:1106.
   PubMed Web of Science ®Google Scholar
• MCCAFFREY JA, SCHER HI: Interstitial pneumonitis following bicalutamide treatment for prostate cancer. Urol. (1998) 160:131.
   Web of Science ®Google Scholar
• WONG PW, MACRIS N, DiFABRIZIO L, SERIFF NS: Eosino-philic lung disease induced by bicalutamide and review of the literature. Chest (1998) 113:548–550.
   PubMed Web of Science ®Google Scholar
• BOLLA M, GONZALEZ D, WARDE P et al.: Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. New Engl. J. Merl. (1997) 337:295–300.
   PubMed Web of Science ®Google Scholar
• PILEPICH MV, CAPLAN R, BYHARDT RW et al.: Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group protocol 85-31. J. Clin. Oncol. (1997) 15:1013–1021.
   PubMed Web of Science ®Google Scholar
• WIRTH MP, IVERSEN P, WILLIAM S et al.: Bicalutamide (Casodex') early prostate cancer (EPC) programme - final demographic data from over 8000 randomised patients. Eur. Urol. (1999) 35\(Suppl. 2):13. Abstract 52. Schellhammer of Urology, East Virginia Medical School, 600 Gresham Drive, River Pavilion Suite 203, Norfolk, VA 23507–1999, USA Tel.: +1 757 668 3572; Fax: +1 757 627 3211;: [email protected]
   Google Scholar